Drugmaker Valeant's bondholders intend to call default

Tue Apr 12, 2016 6:55pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO: Quote) said on Tuesday that it received a notice of default from its bondholders as a result of a delay filing its annual report.

Centerbridge Partners LP issued the notice, but it is not expected to lead to a default, according to people familiar with the matter.

Centerbridge declined to comment.

Valeant said in a statement that it now has until June 11 to make the filing, under its bond agreements, but reiterated its intention to file it on or before April 29.

The company also said the notice of default does not mean it must pay back the bonds faster.

Valeant's bonds were unchanged to half a point lower in late trading on Tuesday, according to IFR.

The Quebec-based drugmaker last week said its lenders had given it an extra month to file the annual report, providing breathing room for the embattled company as it tries to win back investor confidence.

Valeant has faced intense scrutiny and U.S. congressional investigations over its steep price increases for older medicines as well as for other questionable business and accounting practices. Its share price has slid almost 90 percent since last August.

On Monday, the company asked its outgoing Chief Executive Michael Pearson to cooperate with the U.S. Senate Committee on Aging after he failed to show up at a hearing on Friday.   Continued...

The headquarters of Valeant Pharmaceuticals International Inc is seen in Laval, Quebec in this file picture taken November 9, 2015.   REUTERS/Christinne Muschi/Files